K. Naber

M. Pinart, K. Jensen, S. Schmidt, 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

The negative aftermath of prostate biopsy: prophylaxis, complications and antimicrobial stewardship: results of the global prevalence study of infections in urology 2010–2019

F. Bruyère, Z. Tandoğdu, T. Cai, 2021, World Journal of Urology.

Urinary tract infections and bacterial prostatitis in men

K. Naber, F. Wagenlehner, W. Weidner, 2014, Current opinion in infectious diseases.

Appropriate empiric antibiotic choices in health care associated urinary tract infections in urology departments in Europe from 2006 to 2015: A Bayesian analytical approach applied in a surveillance study

Z. Tandoğdu, T. B. Bjerklund Johansen, K. Naber, 2019, PloS one.

The interaction of urinary tract infection and renal insufficiency.

U. Ott, K. Naber, R. Fünfstück, 2006, International journal of antimicrobial agents.

Renal lymph and interstitial fluid concentration of co-trimazine: An experimental study in dogs

K. Naber, P. Madsen, N. Frimodt-Möller, 2005, Infection.

Treatment of Urinary Tract Infections and Antibiotic Stewardship

T. Cai, R. Bartoletti, K. Naber, 2016 .

Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients

W. Witte, I. Klare, P. Heisig, 1994, Infection.

The enigma of prostatitis. Some historical perspectives on the pathogenesis of prostatitis

K. Griffiths, L. Denis, K. Naber, 2006 .

Pulmonary and intranasal delivery of thymoquinone-loaded nanoparticles for Mucormycosis & Covid-19

R. Pitchappan, K. Naber, H. Försterling, 2021, Precision Nanomedicine.

The role of inflammation and infection in the pathogenesis of prostate carcinoma

F. Algaba, R. Hartung, K. Naber, 2007, BJU international.

A new way to prevent urinary tract infections?

K. Naber, F. Wagenlehner, 2017, The Lancet. Infectious diseases.

Pharmacokinetics of the Aminoglycoside Antibiotic Tobramycin in Humans

K. Naber, P. Madsen, S. Westenfelder, 1973, Antimicrobial Agents and Chemotherapy.

Treatment of bacterial urinary tract infections: presence and future.

K. Naber, F. Wagenlehner, 2006, European urology.

Emerging drugs for bacterial urinary tract infections

K. Naber, F. Wagenlehner, W. Weidner, 2005, Expert opinion on emerging drugs.

Understanding clinical variables to improve empirical antibiotic therapy for UTI

K. Naber, F. Wagenlehner, 2019, Nature Reviews Urology.

Does Escherichia coli have pathogenic potential at low level bacteriuria in recurrent, uncomplicated urinary tract infections?

K. Naber, M. Kogan, Y. Naboka, 2020, International journal of antimicrobial agents.

Management of a large healthcare-associated outbreak of Panton-Valentine leucocidin-positive meticillin-resistant Staphylococcus aureus in Germany.

E. Bambl, S. Harbarth, W. Witte, 2007, The Journal of hospital infection.

Antibiotic treatment of uncomplicated urinary tract infection in premenopausal women.

K. Naber, F. Wagenlehner, B. Wullt, 2011, International journal of antimicrobial agents.

[National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients].

K. Naber, E. Hummers-Pradier, W. Vahlensieck, 2011, Der Urologe. Ausg. A.

The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

A. Marchese, K. Naber, H. Botto, 2009, International journal of antimicrobial agents.

[European and Asian guidelines on management and prevention of catheter-associated urinary tract infections].

P. Tambyah, T. Matsumoto, T. B. Bjerklund Johansen, 2008, Urologiia.

Risk factors and predisposing conditions for urinary tract infection

K. Naber, M. Dehesa-Dávila, A. García-Mora, 2019, Therapeutic advances in urology.

Improved Classification of Urinary Tract Infection: Future Considerations

V. Smelov, K. Naber, T. Johansen, 2016 .

Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative

M. Dambros, H. Bauer, K. Naber, 2009 .

Spectrum of bacterial pathogens in uncomplicated and complicated urinary tract infections.

K. Naber, A. Bauernfeind, D. Sauerwein, 1987, European urology.

Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Yanmin Hu, A. Coates, K. Naber, 2019, International journal of antimicrobial agents.

European and Asian guidelines on management and prevention of catheter-associated urinary tract infections.

T. B. Bjerklund Johansen, B. Kovács, K. Naber, 2008, International journal of antimicrobial agents.

Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

H. Niggemann, K. Naber, G. Stein, 2014, BMC Infectious Diseases.

Efficacy and Tolerance of Nitroxoline in the Treatment of Uncomplicated Urinary Tract Infections . Review of the Literature and Individual Patients ’ Data Meta-analysis

H. Niggemann, K. Naber, G. Stein, 2014 .

Guidelines for the perioperative prophylaxis in urological interventions of the urinary and male genital tract.

K. Naber, A. Hofstetter, K. Bichler, 2001, International journal of antimicrobial agents.

Hospital-acquired urinary tract infections.

K. Naber, F. Wagenlehner, 2000, The Journal of hospital infection.

Changes in the management of urinary tract infections in women: impact of the new recommendations on antibiotic prescribing behavior in France, between 2014 and 2019

S. Faure, A. Ramond-Roquin, K. Naber, 2021, BMC Health Services Research.

Classification of oral cephalosporins. A matter for debate.

J. Williams, I. Gould, K. Naber, 2001, International journal of antimicrobial agents.

Antibiotic prophylaxis in urology departments, 2005-2010.

Z. Tandoğdu, T. B. Bjerklund Johansen, K. Naber, 2013, European urology.

Infections Antibiotic Prophylaxis in Urology Departments , 2005 – 2010

Z. Tandoğdu, K. Naber, M. Cek, 2012 .

Prevention of recurrent urinary tract infections: bridging the gap between clinical practice and guidelines in Latin America

K. Naber, J. A. Ortega Martell, J. Milhem Haddad, 2019, Therapeutic advances in urology.

A Randomized, Double-Blind, Parallel-Group, Multicenter Clinical Study of Escherichia coli-Lyophilized Lysate for the Prophylaxis of Recurrent Uncomplicated Urinary Tract Infections

K. Naber, F. Wagenlehner, W. Weidner, 2015, Urologia Internationalis.

Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.

K. Naber, O. Savov, H. Salmen, 2002, International journal of antimicrobial agents.

Asymptomatic Bacteriuria in Elderly Patients

K. Naber, F. Wagenlehner, W. Weidner, 2005, Drugs & aging.

Biomarkers in urinary tract infections – which ones are suitable for diagnostics and follow-up?

K. Naber, J. Horváth, B. Köves, 2020, GMS infectious diseases.

Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection

K. Naber, S. Roth, H. Lange, 1976, European Journal of Clinical Pharmacology.

Sisomicin: Serum Half-Life and Distribution Space in Patients with Normal and Impaired Renal Function

K. Naber, S. Roth, H. Lange, 1976 .

Pharmacokinetics of a new cephalosporin, cephacetrile, in patients with normal and impaired renal function.

K. Naber, P. Madsen, S. Westenfelder, 1974, Arzneimittel-Forschung.

Pharmacokinetics of Temafloxacin in Patients with Liver Impairment

W. Kirch, G. Granneman, M. Kinzig, 1992, Clinical pharmacokinetics.

Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose

F. Sörgel, K. Naber, F. Wagenlehner, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of co-trimoxazole and co-tetroxazine in geriatric patients

W. Weigand, K. Naber, H. Vergin, 1981, Infection.

Urinary tract infection in adults: research priorities and strategies.

A. Schaeffer, L. Nicolle, J. Krieger, 2001, International journal of antimicrobial agents.

New Self-Reporting Questionnaire to Assess Urinary Tract Infections and Differential Diagnosis: Acute Cystitis Symptom Score

K. Naber, F. Wagenlehner, A. Pilatz, 2014, Urologia Internationalis.

Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations.

G. Perletti, V. Magri, K. Naber, 2010, The Journal of urology.

Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications.

V. Orlandi, G. Perletti, V. Magri, 2009, Asian journal of andrology.

Changing concepts on prostatitis

K. Griffiths, L. Denis, K. Naber, 2006 .

Common organisms in urogenital infections with special impact on prostatitis. Discussion

A. Schaeffer, J. Krieger, J. Potts, 2003 .

Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance—non-antibiotic approaches: a systemic review

P. Miotła, K. Naber, T. Rechberger, 2019, Archives of Gynecology and Obstetrics.

Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology.

W. Schneider-Brachert, N. Lehn, K. Naber, 2000, International journal of antimicrobial agents.

Urinary Tract Infections

T. B. Bjerklund Johansen, K. Naber, 2014, Antibiotics.

The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention

S. Schmidt, K. Naber, W. Vahlensieck, 2018, Urologia Internationalis.

[Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline].

S. Schmidt, K. Naber, E. Hummers, 2017, Der Urologe. Ausg. A.

French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy.

Y. Neuzillet, K. Naber, H. Botto, 2012, Medecine et maladies infectieuses.

[Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study].

K. Naber, F. Wagenlehner, G. Schito, 2010, Der Urologe. Ausg. A.

Evaluation by Monte Carlo Simulation of the Pharmacokinetics of Two Doses of Meropenem Administered Intermittently or as a Continuous Infusion in Healthy Volunteers

U. Holzgrabe, C. Landersdorfer, G. Drusano, 2005, Antimicrobial Agents and Chemotherapy.

Co-trimazine distribution in the canine prostate

K. Naber, P. Madsen, N. Frimodt-Möller, 2005, Infection.

Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies.

M. Svendsen, K. Naber, M. Cek, 2006, International journal of antimicrobial agents.

Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic Enterobacteriaceae

K. Naber, F. Wagenlehner, M. Loose, 2019, Antimicrobial Agents and Chemotherapy.

Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.

K. Naber, F. Wagenlehner, M. Loose, 2017, International journal of antimicrobial agents.

Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: Clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy

K. Naber, H. Steindl, F. Wagenlehner, 2020, Investigative and clinical urology.

Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial

K. Naber, H. Steindl, F. Wagenlehner, 2018, Urologia Internationalis.

Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women.

K. Naber, M. Melekos, E. Gerharz, 1997, The Journal of urology.

New drugs for Gram-positive uropathogens.

K. Naber, F. Wagenlehner, 2004, International journal of antimicrobial agents.

Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose

F. Sörgel, K. Naber, F. Wagenlehner, 2003, Antimicrobial Agents and Chemotherapy.

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Richard Colgan, Kalpana Gupta, A. Schaeffer, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria

Denice C. Bay, J. Karlowsky, K. Naber, 2022, Drugs.

[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].

K. Naber, D. Adam, R. Wittenberger, 1986, Infection.

Classification of fluoroquinolones.

K. Naber, D. Adam, 1998, International journal of antimicrobial agents.

[Infection-induced urinary stones].

K. Naber, K. Bichler, E. Eipper, 2003, Der Urologe. Ausg. A.

Infections and urolithiasis: current clinical evidence in prophylaxis and antibiotic therapy.

A. Trinchieri, K. Naber, D. Prezioso, 2008, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

Letter to the Editor: Diagnostic Criteria in Urological Diseases do not Always Match with Findings by Extended Culture Techniques and Metagenomic Sequencing of 16S rDNA

V. Smelov, T. B. Bjerklund Johansen, K. Naber, 2016, Open Microbiology Journal.

Update on biofilm infections in the urinary tract

S. Hultgren, T. B. Bjerklund Johansen, K. Naber, 2012, World Journal of Urology.

Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system.

K. Naber, H. Botto, M. Cek, 2011, International journal of antimicrobial agents.

Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections.

K. Naber, 1999, International journal of antimicrobial agents.

Parenteral/Oral Switch in Complicated Urinary Tract Infection

K. Naber, 1995 .

Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures

T. B. Bjerklund Johansen, K. Naber, H. Botto, 2012, World Journal of Urology.

EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU).

F. Selvaggi, K. Naber, T. Bjerklund-Johansen, 2001, European urology.

Optimal management of urosepsis from the urological perspective.

K. Naber, F. Wagenlehner, W. Weidner, 2007, International journal of antimicrobial agents.

Therapy for prostatitis, with emphasis on bacterial prostatitis

K. Naber, F. Wagenlehner, W. Weidner, 2007, Expert opinion on pharmacotherapy.

58 – Prostatitis, Epididymitis and Orchitis

K. Naber, F. Wagenlehner, W. Weidner, 2017 .

Editorial commentary: asymptomatic bacteriuria--shift of paradigm.

K. Naber, F. Wagenlehner, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevention of recurrent urinary tract infections.

K. Naber, W. Vahlensieck, F. Wagenlehner, 2013, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[Uncomplicated lower urinary tract infections in females--clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy].

K. Leszczynska, K. Naber, G. Schito, 2011, Przeglad epidemiologiczny.

Healthcare-associated urinary tract infections in urology

T. B. Bjerklund Johansen, K. Naber, J. Medina-Polo, 2021, GMS infectious diseases.

Uncomplicated urinary tract infections.

K. Naber, F. Wagenlehner, M. Kaase, 2011, Deutsches Arzteblatt international.

Urosepsis: Overview of the Diagnostic and Treatment Challenges.

K. Naber, F. Wagenlehner, W. Weidner, 2015, Microbiology spectrum.

Infections of the Urogenital Tract

K. Naber, F. Wagenlehner, 2011 .

Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000.

K. Naber, F. Wagenlehner, A. Dalhoff, 2002, International journal of antimicrobial agents.

Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia

K. Naber, 2013, Research and reports in urology.

Renal function during acute total ureteral occlusion and the role of the lymphatics: an experimental study in dogs.

K. Naber, P. Madsen, 1973, The Journal of urology.

Renal function in chronic hydronephrosis with and without infection and the role of the lymphatics. An experimental study in dogs

K. Naber, P. Madsen, 2004, Urological Research.

Ciprofloxacin in the Treatment of Chronic Bacterial Prostatitis

K. Naber, the Trovafloxacin Study Group, J. Focht, 1999, Drugs.

Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections.

I. James, K. Naber, L. Clarysse, 2004, International journal of antimicrobial agents.

Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.

K. Naber, 2002, International journal of antimicrobial agents.

Which fluoroquinolones are suitable for the treatment of urinary tract infections?

K. Naber, K. Naber, 2001, International journal of antimicrobial agents.

Ciprofloxacin in the treatment of chronic bacterial prostatitis : a prospective, non-comparative multicentre clinical trial with long-term follow-up

K. Naber, J. Focht, W. Busch, 2000 .

Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group.

K. Naber, S. Krčméry, 1999, International journal of antimicrobial agents.

The Role of Antibiotics in the Treatment of Chronic Prostatitis:A Consensus Statement

T. B. Bjerklund Johansen, K. Naber, B. Lobel, 1998, European Urology.

Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.

K. Naber, A. Frankenschmidt, W. Bischoff, 1997, The Journal of urology.

Elevated PSA as Differential Diagnostic Error-Source in Prostate Cancer with Consequences in Medical Law

K. Bichler, K. Naber, 2016 .

Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects.

K. Naber, A. Bauernfeind, G. Dietlein, 1987, Scandinavian journal of urology and nephrology. Supplementum.

Thymoquinone: shield and sword against SARS-CoV-2

K. Naber, H. Försterling, A. Sommer, 2020, Precision Nanomedicine.

Pharmacokinetic Characteristics of Antimicrobials and Optimal Treatment of Urosepsis

K. Naber, F. Wagenlehner, W. Weidner, 2007, Clinical pharmacokinetics.

Cephacetrile: Plasma Concentrations during and after Constant Infusion

K. Naber, H. Meyer-Brunot, I. Reitz, 1976 .

[In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].

K. Naber, M. Kresken, B. Körber-Irrgang, 2017, Aktuelle Urologie.

In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections

F. Sörgel, K. Naber, F. Gutzler, 1985, Infection.

In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections

F. Sörgel, K. Naber, F. Gutzler, 2005, Infection.

Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose

K. Naber, F. Wagenlehner, S. Schubert, 2008, Chemotherapy.

Uraemia, psychosis, young patient: an uncommon link

G. Piccoli, K. Naber, F. Wagenlehner, 2006 .

P833 Intravenous therapy with doripenem versus levofioxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis

K. Naber, R. Redman, L. Llorens, 2007 .

Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis

K. Naber, R. Redman, R. Redman, 2009, Antimicrobial Agents and Chemotherapy.

Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue.

G. Perletti, V. Magri, K. Naber, 2009, International journal of antimicrobial agents.

Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections

A. Vente, K. Naber, F. Wagenlehner, 2018, Antimicrobial Agents and Chemotherapy.

Detection of the icaADBC gene cluster and biofilm formation in Staphylococcus epidermidis isolates from catheter-related urinary tract infections.

J. Hacker, K. Naber, W. Ziebuhr, 2002, International journal of antimicrobial agents.

Fleroxacin overview.

K. Naber, 1996, Chemotherapy.

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.

W. Witte, K. Naber, K. Hollauer, 2000, International journal of antimicrobial agents.

Brief report: Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration

F. Sörgel, U. Jaehde, K. Naber, 1989 .

Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration.

F. Sörgel, U. Jaehde, K. Naber, 1989, The American journal of medicine.

Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.

F. Sörgel, K. Naber, F. Wagenlehner, 2006, International journal of antimicrobial agents.

Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.

F. Sörgel, K. Naber, D. Ankel-Fuchs, 2004, International journal of antimicrobial agents.

Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.

A. Markotić, G. Perletti, V. Magri, 2011, Asian journal of andrology.

The role of antibiotics in chronic bacterial prostatitis.

F. Sörgel, K. Naber, F. Wagenlehner, 2005, International journal of antimicrobial agents.

Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg.

M. Kinzig, F. Sörgel, K. Naber, 1993, The Journal of urology.

Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose

F. Sörgel, K. Naber, M. Kinzig‐Schippers, 1998 .

Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination

C. Landersdorfer, M. Kinzig, F. Sörgel, 2011, Chemotherapy.

Concentrations of Gatifloxacin in Plasma and Urine and Penetration into Prostatic and Seminal Fluid, Ejaculate, and Sperm Cells after Single Oral Administrations of 400 Milligrams to Volunteers

F. Sörgel, C. Sauber, K. Naber, 2001, Antimicrobial Agents and Chemotherapy.

Abdominal actinomycosis.

K. Naber, F. Wagenlehner, H. F. Männl, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate.

K. Naber, F. Wagenlehner, S. Schinzel, 2005, European urology.

Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.

F. Sörgel, K. Naber, M. Kinzig‐Schippers, 1999, International journal of antimicrobial agents.

Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis.

K. Naber, V. Schaefer, H. Botto, 2008, International journal of antimicrobial agents.

Prostatitis and male pelvic pain syndrome: diagnosis and treatment.

E. Brähler, K. Naber, F. Wagenlehner, 2009, Deutsches Arzteblatt international.

Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers.

K. Naber, F. Wagenlehner, W. Weidner, 2008, International journal of antimicrobial agents.

Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis

K. Kostev, K. Naber, H. Steindl, 2021, Antibiotics.

The role of quinolones in the treatment of chronic bacterial prostatitis

K. Naber, 1991, Infection.

Antibiotic therapy — rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue

F. Sörgel, K. Naber, 2003 .

In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.

F. Sörgel, K. Naber, H. Grobecker, 1988, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of ciprofloxacin in elderly patients.

G. Meyer, K. Naber, H. Grobecker, 1989, Arzneimittel-Forschung.

Distribution kinetics of enoxacin and its metabolite oxoenoxacin in excretory fluids of healthy volunteers

F. Sörgel, U. Jaehde, K. Naber, 1995, Antimicrobial agents and chemotherapy.

High-performance liquid chromatographic analysis of cefotetan epimers in human plasma and urine.

K. Naber, H. Grobecker, F. Kees, 1984, Journal of chromatography.

Urinary Excretion and Bactericidal Activities of Gemifloxacin and Ofloxacin after a Single Oral Dose in Healthy Volunteers

F. Sörgel, C. Sauber, K. Naber, 2001, Antimicrobial Agents and Chemotherapy.

Treatment of Urinary Tract Infections

W. Stamm, K. Naber, K. Gupta, 2003 .

Urinary Excretion and Bactericidal Activities of a Single Oral Dose of 400 Milligrams of Fleroxacin versus a Single Oral Dose of 800 Milligrams of Pefloxacin in Healthy Volunteers

M. Kinzig, F. Sörgel, U. Theuretzbacher, 1998, Antimicrobial Agents and Chemotherapy.

Renal lymph concentrations of cephalosporins: The importance of protein binding and renal excretion

K. Naber, P. Madsen, 1976, Infection.

[Urinary tract infections in infants and children -- a consensus on diagnostic, therapy and prophylaxis].

W. Rascher, S. Gatermann, J. Thüroff, 2007, Der Urologe (Ausg. A).

Estrogens and aspects of prostate disease

H. Klocker, K. Griffiths, L. Denis, 2007, International journal of urology : official journal of the Japanese Urological Association.

EAU guidelines for the management of genitourinary tuberculosis.

S. Lenk, K. Naber, H. Botto, 2005, European urology.

EAUGuidelines for theManagement of Genitourinary Tuberculosis

S. Lenk, K. Naber, H. Botto, 2005 .

European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS

S. Lenk, F. Selvaggi, A. Heidenreich, 2001 .

EAU Guidelines for the Management of Urinary and Male Genital Tract Infectionstextsuperscript1

F. Selvaggi, K. Naber, T. Bjerklund-Johansen, 2001 .

EAU Guidelines for the Management of Urinary and Male Genital Tract Infections1

F. Selvaggi, K. Naber, T. Bjerklund-Johansen, 2001, European Urology.

Fluoroquinolones in urinary tract infections. Proper and improper use.

K. Naber, 1996, Drugs.

Current challenges in the treatment of complicated urinary tract infections and prostatitis.

K. Naber, F. Wagenlehner, K. Naber, 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Kalkulierte parenterale Initialtherapie bakterieller Infektionen: Infektionen der Nieren und des Urogenitaltrakts

S. Schubert, K. Naber, A. Pilatz, 2020 .

Prostatitis and Male Pelvic Pain Syndrome

E. Brähler, K. Naber, F. Wagenlehner, 2009 .

Chlamydial infections in urology

K. Naber, F. Wagenlehner, W. Weidner, 2006, World Journal of Urology.

Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men

K. Naber, F. Wagenlehner, K. Naber, 2005, Current infectious disease reports.

Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men

K. Naber, F. Wagenlehner, 2004 .

Antimicrobial Treatment of Bacterial Prostatitis

K. Naber, 2003 .

Chronic prostatitis-an infectious disease?

K. Naber, W. Weidner, 2000, The Journal of antimicrobial chemotherapy.

Leading article Chronic prostatitis—an infectious disease?

K. Naber, W. Weidner, 2000 .

[Urinary tract infections].

K. Naber, F. Wagenlehner, W. Weidner, 2014, Aktuelle Urologie.

Validation of the Spanish Acute Cystitis Symptoms Score (ACSS) in native Spanish‐speaking women of Europe and Latin America

K. Naber, F. Wagenlehner, B. Padilla-Fernández, 2022, Neurourology and urodynamics.

Continuous infusion urography in unilateral hydronephrosis.

K. Naber, P. Madsen, H. Kuni, 1975, The Journal of urology.

Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients?

P. Miotła, K. Naber, K. Skorupska, 2018, BioMed research international.

Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

K. Naber, H. Botto, T. Mazzei, 2008, European urology.

Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study.

Z. Tandoğdu, K. Naber, T. Bjerklund-Johansen, 2013, European urology.

Single-dose therapy of uncomplicated urinary tract infections in females — treatment of choice?

K. Naber, 1989, Infection.

Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/Co-trimoxazole

K. Naber, U. Thyroff-Friesinger, 2005, Infection.

Fosfomycin trometamol versus ofloxacin/Co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: A multicentre study

K. Naber, U. Thyroff-Friesinger, 2005, Infection.

Short-term therapy of acute uncomplicated cystitis.

K. Naber, 1999, Current opinion in urology.

Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials.

K. Naber, M. Kresken, W. Baurecht, 1994, International journal of antimicrobial agents.

Uncomplicated urinary tract infections - is single-dose therapy effective?

K. Naber, 1994, International journal of antimicrobial agents.

Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women

K. Naber, E. Koch, 2005, Infection.

Antibacterial Activity of Antibacterial Agents in Urine: An Overview of Applied Methods

K. Naber, 1997 .

REABSORPTION FROM THE RENAL PELVIS AND RENAL FUNCTION DURING TOTAL URETERAL OCCLUSION: AN EXPERIMENTAL STUDY IN DOGS

K. Naber, P. Madsen, 1977 .

Principles of Bacterial Urinary Tract Infections and Antimicrobials

K. Naber, F. Wagenlehner, W. Weidner, 2011 .

Antibiotics and chemotherapeutics in renal lymph. An experimental study in dogs.

K. Naber, P. Madsen, K. Bichler, 1976, Investigative urology.

Urinary Concentrations and Antibacterial Activities of Nitroxoline at 250 Milligrams versus Trimethoprim at 200 Milligrams against Uropathogens in Healthy Volunteers

W. Pfister, K. Naber, F. Wagenlehner, 2013, Antimicrobial Agents and Chemotherapy.

The gene profile of Enterobacteriaceae virulence factors in relation to bacteriuria levels between the acute episodes of recurrent uncomplicated lower urinary tract infection

K. Naber, M. Kogan, Y. Naboka, 2020, Expert review of anti-infective therapy.

Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects

K. Naber, F. Wagenlehner, M. Straubinger, 2016, Antimicrobial Agents and Chemotherapy.

An update on uncomplicated urinary tract infections in women

K. Naber, F. Wagenlehner, W. Weidner, 2009, Current opinion in urology.

Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran--a prospective multicenter point prevalence study.

N. Beeching, F. Moradi, E. Alp, 2014, Journal of Infection.

Prevalence of hospital-acquired urinary tract infections in urology departments.

T. B. Bjerklund Johansen, M. Svendsen, K. Naber, 2007, European urology.

The importance of the pressure in the prostatic fossa and absorption of irrigating fluid during transurethral resection of the prostate.

K. Naber, P. Madsen, 1973, The Journal of urology.

Absorption and excretion of sorbitol and mannitol in transurethral resection of the prostate.

K. Naber, P. Madsen, 1974, Investigative urology.

Urinary tract infection in patients with diabetes mellitus.

M. Hanefeld, L. Nicolle, K. Naber, 2012, Clinical nephrology.

Various methods of determining irrigating fluid absorption during transurethal resection of the prostate

K. Naber, P. Madsen, H. Kuni, 1973, Urological Research.

[Measurement of absorption of irrigating fluids during transurethral resection of the prostate (TUR) and its clinical importance].

K. Naber, K. Bichler, H. Sommerkamp, 1971, Der Urologe.

Multidisciplinary approach to prostatitis.

S. Cuzzocrea, G. Morgia, G. Russo, 2019, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

A step further in a vaccine for Escherichia coli.

K. Naber, F. Wagenlehner, 2019, Lancet. Infectious Diseases (Print).

In vitro Activity of Daptomycin versus Linezolid and Vancomycin against Gram-Positive Uropathogens and Ampicillin against Enterococci, Causing Complicated Urinary Tract Infections

W. Witte, N. Lehn, K. Naber, 2005, Chemotherapy.

Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003–2013

Z. Tandoğdu, K. Naber, M. Cek, 2015, World Journal of Urology.

Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005.

K. Naber, F. Wagenlehner, W. Weidner, 2008, International Journal of Antimicrobial Agents.

Epidemiology of Extrapulmonary Tuberculosis

K. Naber, T. Johansen, E. Kulchavenya, 2019, Extrapulmonary Tuberculosis.

Urogenital Tuberculosis: Classification, Diagnosis, and Treatment

K. Naber, T. Johansen, E. Kulchavenya, 2016 .

Antibiotics and Resistance of Uropathogens

K. Naber, F. Wagenlehner, 2004 .

Summary consensus statement: Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome

A. Schaeffer, J. Krieger, J. Nickel, 2003 .

[Infections of the urinary tract and male genitalia].

K. Naber, A. Hofstetter, W. Vahlensieck, 2006, Der Urologe (Ausg. A).

Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study.

V. Boddi, P. Gontero*, T. Cai, 2007, The Journal of urology.

Prostatitis: the role of antibiotic treatment

K. Naber, F. Wagenlehner, 2003, World Journal of Urology.

Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid

M. Kinzig, F. Sörgel, K. Naber, 1993, Infection.

Proposed study design in prostatitis

K. Naber, H. Giamarellou, 2005, Infection.

Chlamydial infections and prostatitis in men

K. Naber, F. Wagenlehner, W. Weidner, 2006, BJU international.

Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study

K. Naber, F. Wagenlehner, S. Ballarini, 2014, World Journal of Urology.

P1382 Concentrations of moxifioxacin (400 mg) in prostatic secretions and ejaculate after a single oral dose in healthy volunteers

K. Naber, F. Wagenlehner, W. Weidner, 2007 .

The Assessment and Management of Male Pelvic Pain Syndrome, Including Prostatitis (Part I)

A. Schaeffer, J. Krieger, L. Nyberg, 2006 .

Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010

Z. Tandoğdu, K. Naber, T. Bjerklund-Johansen, 2014, World Journal of Urology.

Epidemiology, treatment and prevention of healthcare-associated urinary tract infections

H. Kiyota, K. Naber, T. Bjerklund-Johansen, 2012, World Journal of Urology.

Antibiotics in urology: new essentials.

K. Naber, F. Wagenlehner, W. Weidner, 2008, The Urologic clinics of North America.

Activity of cefroxadine and cephalexin in urinary tract infections: A double-blind comparative study

K. Naber, T. Ahrens, 2005, Infection.

Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches.

M. Roberts, K. Naber, P. Harris, 2017, Urology.

Harnwegsinfektionen: Zystitis, Pyelonephritis, Urosepsis

K. Naber, F. Wagenlehner, R. Fünfstück, 2012, DMW Deutsche Medizinische Wochenschrift.

Ciprofloxacin 250 mg Twice Daily Versus Ofloxacin 200 mg Twice Daily in the Treatment of Complicated Urinary Tract Infections in Women

I. Yaniv, K. Naber, R. Raz, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

Patient assessment in urinary tract infections: symptoms, risk factors and antibiotic treatment options

K. Naber, P. Tenke, F. Wagenlehner, 2011 .

Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic/pharmacodynamic considerations.

K. Naber, F. Wagenlehner, W. Weidner, 2005, The Journal of hospital infection.

[Rational antibiotic therapy of urinary tract infections].

K. Naber, F. Wagenlehner, W. Weidner, 2008, Medizinische Monatsschrift fur Pharmazeuten.

Improved diagnostics of chronic inflammatory prostatitis.

K. Naber, E. Kulchavenya, Khomyakov, 2012, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

The Bacterial Insertion Sequence Element IS256 Occurs Preferentially in Nosocomial Staphylococcus epidermidis Isolates: Association with Biofilm Formation and Resistance to Aminoglycosides

R. Marre, K. Naber, W. Ziebuhr, 2004, Infection and Immunity.

Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT)

K. Naber, D. Zingg, F. Wagenlehner, 2018, Expert review of pharmacoeconomics & outcomes research.

Wagenlehner F. Antimicrobial Resistance in Urosepsis: Outcomes from the Multinational, Multicenter Global Prevalence of Infections in Urology (GPIU)

Z. Tandoğdu, K. Naber, M. Cek, 2015 .

Bearberry in the treatment of acute uncomplicated cystitis (BRUMI): protocol of a multicentre, randomised double-blind clinical trial

P. Hegyi, P. Nyirády, K. Naber, 2022, BMJ Open.

Effect of a Herbal Therapy on Clinical Symptoms of Acute Lower Uncomplicated Urinary Tract Infections in Women: Secondary Analysis from a Randomized Controlled Trial

K. Naber, R. Fischer, W. Vahlensieck, 2019, Antibiotics.

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women

K. Naber, P. Tenke, F. Wagenlehner, 2019, World journal of urology.

[Urinary tract infection - diagnosis].

K. Naber, F. Wagenlehner, 2001, Deutsche medizinische Wochenschrift.

Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II

K. Naber, P. Tenke, F. Wagenlehner, 2019, World Journal of Urology.

The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version

K. Naber, P. Tenke, F. Wagenlehner, 2017, Central European journal of urology.

Clinical Validation of the Greek Version of the Acute Cystitis Symptom Score (ACSS)—Part II

K. Naber, K. Stamatiou, F. Wagenlehner, 2021, Antibiotics.

Linguistic and clinical validation of the acute cystitis symptom score in German-speaking Swiss women with acute cystitis

T. B. Bjerklund Johansen, K. Naber, F. Wagenlehner, 2021, International Urogynecology Journal.

Clinical Validation of the Greek Version of the Acute Cystitis Symptom Score (ACSS). Part II

K. Naber, K. Stamatiou, F. Wagenlehner, 2021 .

Acute Cystitis Symptom Score (ACSS): Clinical Validation of the Italian Version

T. Cai, R. Bartoletti, K. Naber, 2020, Antibiotics.

Editorial Comment.

K. Naber, F. Wagenlehner, 2019, The Journal of urology.

Recent research in urological infections

K. Naber, F. Wagenlehner, 2019, Nature Reviews Urology.

Reliability of Symptom-Based Diagnosis of Uncomplicated Cystitis

K. Naber, F. Wagenlehner, A. Pilatz, 2018, Urologia Internationalis.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part II. Patient-Reported Outcome Assessment

K. Naber, F. Wagenlehner, A. Pilatz, 2018, Antibiotics.

The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections

Z. Tandoğdu, T. Cai, R. Bartoletti, 2016, Pathogens.

Emergence of antibiotic resistance and prudent use of antibiotic therapy in nosocomially acquired urinary tract infections.

K. Naber, F. Wagenlehner, 2004, International journal of antimicrobial agents.

Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study

Z. Tandoğdu, T. B. Bjerklund Johansen, K. Naber, 2013, World Journal of Urology.

Psychosocial burden of recurrent uncomplicated urinary tract infections

K. Naber, F. Wagenlehner, José Tirán-Saucedo, 2022, GMS infectious diseases.

Novel Antibiotics in the Treatment of Urinary Tract Infections.

K. Naber, F. Wagenlehner, 2019, European urology focus.

Anti-Biofilm Effect of Octenidine and Polyhexanide on Uropathogenic Biofilm-Producing Bacteria

K. Naber, F. Wagenlehner, M. Loose, 2021, Urologia Internationalis.

2 IMPORTANT FEATURES OF NOSOCOMIAL URINARY TRACT INFECTIONS IN UROLOGY DEPARTMENTS. DATA FROM THE PEP AND PEAP-STUDIES

M. Svendsen, K. Naber, M. Cek, 2007 .

Epidemiological analysis of the spread of pathogens from a urological ward using genotypic, phenotypic and clinical parameters.

C. Held, W. Witte, I. Klare, 2002, International journal of antimicrobial agents.

Targeted, immediate antibiotics following a positive dipstick test may be the optimal management strategy

K. Naber, 2010, Evidence Based Medicine.

Cefiderocol for treatment of complicated urinary tract infections.

K. Naber, F. Wagenlehner, 2019, The Lancet. Infectious diseases.

Reevaluation of the Acute Cystitis Symptom Score, a Self-Reporting Questionnaire. Part I. Development, Diagnosis and Differential Diagnosis

K. Naber, F. Wagenlehner, A. Pilatz, 2018, Antibiotics.

Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU).

Z. Tandoğdu, K. Naber, T. Bjerklund-Johansen, 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative

M. Carini, A. Cocci, T. Cai, 2017, World Journal of Urology.

Thromboembolische Komplikationen unter Thromboembolieprophylaxe

K. Naber, P. Sterr, 2002 .

The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment

K. Naber, F. Wagenlehner, A. Pilatz, 2016, Urologia Internationalis.

Safety and Efficacy of Intravenous Doripenem for the Treatment of Complicated Urinary Tract Infections and Pyelonephritis

K. Naber, R. Redman, R. Redman, 2010, Journal of chemotherapy.

Chronic bacterial prostatitis.

K. Naber, F. Wagenlehner, W. Weidner, 1983, The Lancet.

Fosfomycin Trometamol (3,000 mg) in Perioperative Antibiotic Prophylaxis of Healthcare-Associated Infections after Endourological Interventions: A Narrative Review

K. Naber, F. Wagenlehner, P. M. Thomas, 2013, Urologia internationalis.

Fosfomycin Trometamol in Patients with Renal Insufficiency and in the Elderly

K. Naber, P. M. Thomas, R. Fünfstück, 2012 .

Concentrations of ceftriaxone in prostate adenoma tissue.

K. Naber, D. Adam, 1984, Chemotherapy.

The EAU and AUA/CUA/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference?

K. Naber, F. Wagenlehner, G. Bonkat, 2020, European Urology.

Incidence of nosocomial urinary tract infections on a surgical intensive care unit and implications for management.

K. Naber, H. Vogel, F. Wagenlehner, 2006, International journal of antimicrobial agents.

Non-antibiotic herbal therapy of uncomplicated lower urinary tract infection in women – a pilot study

K. Naber, H. Steindl, D. Abramov-Sommariva, 2013 .

A global perspective on improving patient care in uncomplicated urinary tract infection: Expert consensus and practical guidance.

L. Nicolle, M. Wilcox, A. Stapleton, 2021, Journal of global antimicrobial resistance.

Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.

Yanmin Hu, A. Coates, K. Naber, 2018, International journal of antimicrobial agents.

Postoperative Prevention of Urinary Tract Infections in Patients after Urogynecological Surgeries—Nonantibiotic Herbal (Canephron) versus Antibiotic Prophylaxis (Fosfomycin Trometamol): A Parallel-Group, Randomized, Noninferiority Experimental Trial

P. Miotła, K. Naber, T. Rechberger, 2022, Pathogens.

The Acute Cystitis Symptom Score for Patient-Reported Outcome Assessment.

K. Naber, F. Wagenlehner, A. Pilatz, 2016, Urologia internationalis.

Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study.

Mathias W Pletz, S. Hagel, O. Makarewicz, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The revival of old antibiotics for treatment of uncomplicated urinary tract infections in the era of antibiotic stewardship

S. Schmidt, K. Naber, F. Mandraka, 2017, Current opinion in urology.

Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated

K. Naber, Y. Naboka, K. Ibishev, 2022, Investigative and clinical urology.

Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review.

M. Kinzig, F. Sorgel, K. Naber, 1991, The American journal of medicine.

Diagnosis of acute cystitis in primary care: symptom-based versus urinalysis-based diagnosis

M. Bouvy, E. Koster, K. Naber, 2022, Primary Health Care Research & Development.

P186 New self-administering tool for assessing urinary symptoms and quality of life in female patients with acute uncomplicated cystitis

K. Naber, F. Wagenlehner, F. Akilov, 2013 .

Rapid resolution of symptoms with ciprofloxacin therapy in 3859 hospitalised patients with urinary tract infection.

K. Naber, H. Landen, 2004, International Journal of Antimicrobial Agents.

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.

K. Naber, A. Geddes, F. di Silverio, 1996, Journal of Antimicrobial Chemotherapy.

37 Infective complications after prostate biopsy: Outcome of the Global Prevalence of Infections in Urology (GPIU) prostate biopsy side study 2010 – a multinational, multicenter study

Z. Tandoğdu, K. Naber, T. Bjerklund-Johansen, 2012 .

[Clinical significance of bacterial beta-lactamase production in the treatment of urinary tract infections with oral beta-lactam-antibiotics].

W. Zimmermann, K. Naber, T. Ahrens, 1982, Der Urologe. Ausg. A.

Are the Fluoroquinolones Comparable in the Treatment of Urinary Tract Infections?

K. Naber, 1999, Drugs.

Urinary Excretion and Bactericidal Activity of Intravenous Ciprofloxacin Compared with Oral Ciprofloxacin

H. Stass, U. Theuretzbacher, K. Naber, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Translation and validation of the Korean version of acute cystitis symptom score

K. Naber, F. Wagenlehner, Seung-ju Lee, 2022, Investigative and clinical urology.

In vitro Activity of Enoxacin versus Ciprofloxacin, Fleroxacin, Lomefloxacin, Ofloxacin, Pefloxacin, and Rufloxacin against Uropathogens

W. Witte, K. Naber, K. Hollauer, 1998, Chemotherapy.

Anti-infective treatment of bacterial urinary tract infections.

G. Perletti, K. Naber, F. Wagenlehner, 2008, Current medicinal chemistry.

Effect of Different Media on the Bactericidal Activity of Colistin and on the Synergistic Combination With Azidothymidine Against mcr-1-Positive Colistin-Resistant Escherichia coli

Yanmin Hu, A. Coates, K. Naber, 2020, Frontiers in Microbiology.

Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers.

F. Sörgel, U. Jaehde, K. Naber, 1989, The American journal of medicine.

Critical issues in chronic prostatitis.

G. Morgia, T. Cai, G. Perletti, 2010, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

Urogenital infections: The pivotal role of the urologist.

K. Naber, 2006, European urology.

Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.

F. Sorgel, K. Naber, P. Muth, 1988, The Journal of antimicrobial chemotherapy.

Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.

K. Naber, H. Grobecker, F. Kees, 1986, The Journal of antimicrobial chemotherapy.

Cefotaxime in urinary tract infections

K. Naber, 1989, Infection.

[Traumatic renal pelvis rupture associated with previously unknown stenosis at the renal pelvis junction].

K. Naber, F. Wagenlehner, P. Sterr, 2003, Aktuelle Urologie.

[Enoxacin--comparative pharmacokinetics and tissue penetration].

F. Sörgel, A. Morgenroth, K. Naber, 1989, Infection.

The Global Prevalence of Infections in Urology (GPUI) Study: A Worldwide Surveillance Study in Urology Patients.

Z. Tandoğdu, T. Cai, T. B. Bjerklund Johansen, 2016, European urology focus.

Clinical Efficacy of Pefloxacin in Complicated Urinary Tract Infections, Uncomplicated Gonococcal Urethritis, Prostatitis and Epididymitis

K. Naber, 1996 .

In Vitro Activity and Concentrations in Serum, Urine, Prostatic Secretion and Adenoma Tissue of Ofloxacin in Urological Patients

K. Naber, D. Adam, F. Kees, 2012, Drugs.

Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women : A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

A. Schaeffer, L. Nicolle, G. Moran, 2011 .

Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction.

A. Markotić, G. Perletti, V. Magri, 2011, Asian journal of andrology.

Multidisciplinary approach to prostatitis.

S. Cuzzocrea, G. Morgia, G. Russo, 2019, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis.

A. Schaeffer, K. Naber, Yong‐Hyun Cho, 2009, International journal of antimicrobial agents.

Emerging drugs for bacterial urinary tract infections

G. Perletti, K. Naber, F. Wagenlehner, 2005, Expert opinion on emerging drugs.

Prescribing behavior in urinary tract infection: inadequate implementation of guidelines in clinical practice.

K. Naber, F. Wagenlehner, 2012, Deutsches Arzteblatt international.

Prescribing Behavior in Urinary Tract InfectionImplementation of Guidelines in Clinical Practice

K. Naber, F. Wagenlehner, 2012 .

Clinical Practice Guideline: Uncomplicated Urinary Tract Infections

K. Naber, G. Schmiemann, U. Hoyme, 2012 .

Harnwegsinfektionen: Konsensus? - Erwiderung

K. Naber, U. Sester, 2006 .

High-performance liquid chromatography analysis of mezlocillin, piperacillin, their degradation products, and of ioxitalamic acid in plasma and urine of healthy volunteers.

G. Meyer, K. Naber, H. Grobecker, 1985, Arzneimittel-Forschung.

Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.

K. Naber, H. Botto, T. Mazzei, 2008, European urology.